| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 68 | 2025 | 322 | 16.050 |
Why?
|
| Antirheumatic Agents | 58 | 2024 | 214 | 14.070 |
Why?
|
| Gout | 18 | 2020 | 48 | 5.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 22 | 2024 | 588 | 3.630 |
Why?
|
| Gout Suppressants | 11 | 2020 | 22 | 3.280 |
Why?
|
| Biological Products | 12 | 2024 | 90 | 3.000 |
Why?
|
| Registries | 39 | 2025 | 799 | 2.860 |
Why?
|
| Medication Adherence | 13 | 2018 | 241 | 2.660 |
Why?
|
| Rituximab | 4 | 2017 | 80 | 2.020 |
Why?
|
| Abatacept | 5 | 2024 | 64 | 1.990 |
Why?
|
| Severity of Illness Index | 30 | 2025 | 1479 | 1.870 |
Why?
|
| Rheumatology | 11 | 2020 | 66 | 1.840 |
Why?
|
| Middle Aged | 87 | 2025 | 16314 | 1.830 |
Why?
|
| Aged | 82 | 2025 | 13406 | 1.830 |
Why?
|
| Arthritis, Psoriatic | 6 | 2024 | 33 | 1.740 |
Why?
|
| Male | 101 | 2025 | 27747 | 1.640 |
Why?
|
| Practice Patterns, Physicians' | 11 | 2016 | 692 | 1.570 |
Why?
|
| Female | 102 | 2025 | 30724 | 1.540 |
Why?
|
| Treatment Outcome | 38 | 2024 | 5281 | 1.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2020 | 725 | 1.420 |
Why?
|
| United States | 35 | 2025 | 7426 | 1.360 |
Why?
|
| Sjogren's Syndrome | 2 | 2020 | 24 | 1.350 |
Why?
|
| Humans | 133 | 2025 | 59389 | 1.340 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 2 | 2019 | 6 | 1.240 |
Why?
|
| Guideline Adherence | 6 | 2020 | 292 | 1.140 |
Why?
|
| Adult | 52 | 2024 | 15683 | 1.120 |
Why?
|
| Disease Progression | 6 | 2025 | 1119 | 1.090 |
Why?
|
| Antibodies, Monoclonal | 8 | 2019 | 836 | 1.080 |
Why?
|
| Etanercept | 7 | 2019 | 32 | 1.040 |
Why?
|
| Adalimumab | 6 | 2019 | 30 | 1.010 |
Why?
|
| Methotrexate | 7 | 2022 | 76 | 0.980 |
Why?
|
| Pyrroles | 1 | 2024 | 45 | 0.930 |
Why?
|
| Piperidines | 1 | 2024 | 55 | 0.920 |
Why?
|
| Pyrimidines | 1 | 2024 | 131 | 0.890 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 170 | 0.860 |
Why?
|
| Rheumatologists | 4 | 2020 | 7 | 0.830 |
Why?
|
| Health Resources | 3 | 2019 | 88 | 0.820 |
Why?
|
| Prescription Drugs | 2 | 2013 | 47 | 0.810 |
Why?
|
| Prospective Studies | 13 | 2025 | 3067 | 0.790 |
Why?
|
| Churg-Strauss Syndrome | 3 | 2007 | 11 | 0.760 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2021 | 202 | 0.750 |
Why?
|
| Colchicine | 4 | 2020 | 27 | 0.730 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 551 | 0.710 |
Why?
|
| Quality of Health Care | 4 | 2015 | 513 | 0.670 |
Why?
|
| Cohort Studies | 20 | 2019 | 2375 | 0.640 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 2338 | 0.640 |
Why?
|
| Health Maintenance Organizations | 5 | 2010 | 59 | 0.630 |
Why?
|
| Aged, 80 and over | 26 | 2018 | 5119 | 0.610 |
Why?
|
| Remission Induction | 9 | 2020 | 137 | 0.600 |
Why?
|
| Patient Compliance | 3 | 2010 | 349 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2016 | 217 | 0.600 |
Why?
|
| Managed Care Programs | 3 | 2013 | 88 | 0.590 |
Why?
|
| Time Factors | 18 | 2021 | 3615 | 0.590 |
Why?
|
| Certolizumab Pegol | 1 | 2018 | 2 | 0.590 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2017 | 36 | 0.580 |
Why?
|
| Inservice Training | 1 | 2018 | 81 | 0.560 |
Why?
|
| Drug Substitution | 2 | 2016 | 40 | 0.560 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 95 | 0.560 |
Why?
|
| Depression | 5 | 2016 | 829 | 0.550 |
Why?
|
| Biological Factors | 1 | 2016 | 21 | 0.540 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 674 | 0.520 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2007 | 29 | 0.510 |
Why?
|
| Precision Medicine | 1 | 2017 | 102 | 0.500 |
Why?
|
| Osteoarthritis | 3 | 2008 | 131 | 0.490 |
Why?
|
| Sex Characteristics | 1 | 2017 | 197 | 0.490 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2020 | 126 | 0.490 |
Why?
|
| Drug Costs | 2 | 2013 | 54 | 0.490 |
Why?
|
| Bacterial Infections | 1 | 2016 | 140 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 454 | 0.480 |
Why?
|
| Ambulatory Care | 3 | 2014 | 304 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 705 | 0.440 |
Why?
|
| Prevalence | 9 | 2020 | 1253 | 0.440 |
Why?
|
| Immunoconjugates | 1 | 2013 | 85 | 0.430 |
Why?
|
| Psoriasis | 3 | 2020 | 50 | 0.420 |
Why?
|
| Algorithms | 6 | 2016 | 974 | 0.420 |
Why?
|
| Arthritis, Juvenile | 1 | 2013 | 7 | 0.420 |
Why?
|
| Surveys and Questionnaires | 13 | 2020 | 2516 | 0.420 |
Why?
|
| Drug Therapy, Combination | 5 | 2024 | 451 | 0.420 |
Why?
|
| Incidence | 11 | 2019 | 1238 | 0.400 |
Why?
|
| Culture | 1 | 2012 | 73 | 0.390 |
Why?
|
| Disease Management | 4 | 2020 | 220 | 0.390 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 902 | 0.380 |
Why?
|
| Asthma | 2 | 2007 | 460 | 0.380 |
Why?
|
| Retrospective Studies | 13 | 2019 | 6071 | 0.380 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 6 | 2013 | 140 | 0.370 |
Why?
|
| Population Surveillance | 1 | 2012 | 195 | 0.370 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 312 | 0.370 |
Why?
|
| Primary Health Care | 4 | 2016 | 648 | 0.360 |
Why?
|
| Health Expenditures | 1 | 2012 | 116 | 0.360 |
Why?
|
| Hospitalization | 5 | 2016 | 1290 | 0.350 |
Why?
|
| Anticoagulants | 5 | 2012 | 480 | 0.350 |
Why?
|
| Pain Measurement | 7 | 2019 | 327 | 0.350 |
Why?
|
| Self Care | 1 | 2012 | 207 | 0.350 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2024 | 24 | 0.350 |
Why?
|
| Chi-Square Distribution | 5 | 2019 | 409 | 0.340 |
Why?
|
| Nursing Homes | 7 | 2015 | 661 | 0.340 |
Why?
|
| Odds Ratio | 5 | 2023 | 746 | 0.340 |
Why?
|
| Uric Acid | 5 | 2019 | 45 | 0.330 |
Why?
|
| Age Factors | 9 | 2017 | 1504 | 0.330 |
Why?
|
| Hyperuricemia | 2 | 2019 | 7 | 0.320 |
Why?
|
| Health Surveys | 5 | 2017 | 298 | 0.320 |
Why?
|
| Glucocorticoids | 4 | 2023 | 180 | 0.320 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2016 | 119 | 0.310 |
Why?
|
| Linear Models | 3 | 2018 | 403 | 0.300 |
Why?
|
| Polyarteritis Nodosa | 1 | 2008 | 3 | 0.300 |
Why?
|
| Consensus | 3 | 2019 | 193 | 0.300 |
Why?
|
| Pancytopenia | 1 | 2008 | 7 | 0.300 |
Why?
|
| Propensity Score | 3 | 2018 | 144 | 0.290 |
Why?
|
| Risk Factors | 9 | 2019 | 4986 | 0.290 |
Why?
|
| Insurance Claim Review | 2 | 2012 | 76 | 0.290 |
Why?
|
| Spondylarthritis | 2 | 2020 | 40 | 0.290 |
Why?
|
| Disability Evaluation | 5 | 2015 | 199 | 0.290 |
Why?
|
| Accidents, Occupational | 1 | 2008 | 42 | 0.290 |
Why?
|
| Rheumatic Diseases | 1 | 2008 | 38 | 0.290 |
Why?
|
| Uricosuric Agents | 2 | 2020 | 2 | 0.280 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 861 | 0.280 |
Why?
|
| Cross-Sectional Studies | 7 | 2017 | 2380 | 0.270 |
Why?
|
| Allopurinol | 4 | 2020 | 15 | 0.270 |
Why?
|
| Long-Term Care | 3 | 2008 | 176 | 0.270 |
Why?
|
| Databases, Factual | 10 | 2019 | 814 | 0.270 |
Why?
|
| Pain | 3 | 2020 | 396 | 0.270 |
Why?
|
| Symptom Assessment | 2 | 2017 | 44 | 0.260 |
Why?
|
| Logistic Models | 3 | 2019 | 1234 | 0.260 |
Why?
|
| Chronic Disease | 4 | 2015 | 717 | 0.260 |
Why?
|
| Prognosis | 4 | 2018 | 1597 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2019 | 805 | 0.260 |
Why?
|
| Health Status | 4 | 2020 | 426 | 0.250 |
Why?
|
| Predictive Value of Tests | 9 | 2015 | 1027 | 0.250 |
Why?
|
| Warfarin | 3 | 2012 | 105 | 0.240 |
Why?
|
| Research Design | 3 | 2024 | 555 | 0.240 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 229 | 0.240 |
Why?
|
| Quality of Life | 4 | 2020 | 1137 | 0.230 |
Why?
|
| Adipokines | 1 | 2024 | 28 | 0.230 |
Why?
|
| Cluster Analysis | 4 | 2023 | 245 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 396 | 0.230 |
Why?
|
| Feasibility Studies | 2 | 2018 | 526 | 0.230 |
Why?
|
| Arthralgia | 2 | 2015 | 55 | 0.220 |
Why?
|
| Knee Joint | 3 | 2016 | 285 | 0.220 |
Why?
|
| Massachusetts | 7 | 2014 | 2019 | 0.220 |
Why?
|
| Self Report | 3 | 2016 | 359 | 0.210 |
Why?
|
| Metabolic Syndrome | 1 | 2024 | 131 | 0.210 |
Why?
|
| Immunoglobulin G | 4 | 2012 | 446 | 0.210 |
Why?
|
| Delphi Technique | 3 | 2019 | 77 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 114 | 0.210 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 515 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1051 | 0.210 |
Why?
|
| Cost of Illness | 1 | 2024 | 156 | 0.200 |
Why?
|
| Sex Factors | 5 | 2013 | 935 | 0.200 |
Why?
|
| Neoplasms | 3 | 2022 | 1231 | 0.200 |
Why?
|
| Adolescent | 10 | 2016 | 5838 | 0.200 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 168 | 0.200 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 284 | 0.200 |
Why?
|
| Patient Selection | 2 | 2015 | 465 | 0.200 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 19 | 0.190 |
Why?
|
| Attitude | 1 | 2002 | 96 | 0.190 |
Why?
|
| Health Services | 1 | 2002 | 81 | 0.190 |
Why?
|
| Sulfasalazine | 1 | 2021 | 5 | 0.190 |
Why?
|
| Quality Improvement | 2 | 2017 | 418 | 0.190 |
Why?
|
| Obesity | 3 | 2022 | 1166 | 0.190 |
Why?
|
| Databases as Topic | 3 | 2007 | 52 | 0.190 |
Why?
|
| North America | 3 | 2016 | 105 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 19 | 0.190 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 292 | 0.190 |
Why?
|
| Cardiac Catheterization | 1 | 2003 | 253 | 0.180 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 275 | 0.180 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 789 | 0.180 |
Why?
|
| Homes for the Aged | 3 | 2012 | 157 | 0.180 |
Why?
|
| Joints | 3 | 2012 | 32 | 0.180 |
Why?
|
| Comorbidity | 3 | 2020 | 1078 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 413 | 0.170 |
Why?
|
| Osteoarthritis, Knee | 2 | 2016 | 380 | 0.170 |
Why?
|
| Diphosphonates | 2 | 2010 | 31 | 0.170 |
Why?
|
| Women's Health | 1 | 2003 | 360 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2012 | 62 | 0.170 |
Why?
|
| Ustekinumab | 1 | 2020 | 1 | 0.170 |
Why?
|
| Infliximab | 4 | 2012 | 49 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2012 | 45 | 0.170 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 149 | 0.160 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 20 | 0.160 |
Why?
|
| Medicare | 4 | 2023 | 601 | 0.160 |
Why?
|
| Fatigue | 1 | 2020 | 103 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2016 | 202 | 0.160 |
Why?
|
| Crystal Arthropathies | 1 | 2019 | 1 | 0.160 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 399 | 0.160 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 85 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 133 | 0.150 |
Why?
|
| Diuretics | 2 | 2017 | 59 | 0.150 |
Why?
|
| Recurrence | 2 | 2017 | 602 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 742 | 0.150 |
Why?
|
| Health Care Surveys | 2 | 2013 | 278 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 206 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2017 | 84 | 0.130 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2008 | 43 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 147 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 365 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2016 | 61 | 0.130 |
Why?
|
| Nursing Staff | 2 | 2013 | 39 | 0.130 |
Why?
|
| Patients | 2 | 2013 | 103 | 0.120 |
Why?
|
| Drug Utilization | 2 | 2015 | 208 | 0.120 |
Why?
|
| Age Distribution | 2 | 2008 | 249 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 46 | 0.120 |
Why?
|
| Medication Errors | 5 | 2012 | 109 | 0.120 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 23 | 0.120 |
Why?
|
| California | 4 | 2016 | 161 | 0.120 |
Why?
|
| Heart Failure | 2 | 2012 | 853 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2007 | 241 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 1091 | 0.110 |
Why?
|
| Medicare Part B | 2 | 2012 | 11 | 0.110 |
Why?
|
| Immunologic Factors | 2 | 2012 | 103 | 0.110 |
Why?
|
| Osteoporosis | 2 | 2012 | 102 | 0.110 |
Why?
|
| Office Visits | 1 | 2014 | 42 | 0.110 |
Why?
|
| Longitudinal Studies | 5 | 2016 | 1189 | 0.110 |
Why?
|
| Acute Disease | 2 | 2013 | 658 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2019 | 1925 | 0.110 |
Why?
|
| Medical Staff | 1 | 2013 | 13 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2013 | 1793 | 0.110 |
Why?
|
| Arthroplasty, Replacement | 1 | 2013 | 15 | 0.110 |
Why?
|
| Administrative Personnel | 1 | 2013 | 29 | 0.110 |
Why?
|
| Autoimmune Diseases | 2 | 2012 | 220 | 0.110 |
Why?
|
| Connecticut | 4 | 2015 | 86 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2013 | 19 | 0.100 |
Why?
|
| Patient Discharge | 2 | 2014 | 492 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 42 | 0.100 |
Why?
|
| Seafood | 1 | 2012 | 12 | 0.100 |
Why?
|
| Dementia | 2 | 2013 | 248 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 170 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 168 | 0.100 |
Why?
|
| Sampling Studies | 1 | 2012 | 65 | 0.100 |
Why?
|
| Meat | 1 | 2012 | 33 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2003 | 244 | 0.100 |
Why?
|
| Medicare Part D | 1 | 2012 | 37 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2013 | 137 | 0.100 |
Why?
|
| Income | 1 | 2013 | 157 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 29 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 570 | 0.090 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2013 | 129 | 0.090 |
Why?
|
| Life Style | 1 | 2013 | 299 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2013 | 279 | 0.090 |
Why?
|
| ROC Curve | 2 | 2009 | 267 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 154 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2017 | 619 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 90 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2014 | 342 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 168 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 332 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 44 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 415 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 288 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2011 | 136 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2010 | 41 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2014 | 421 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2010 | 126 | 0.080 |
Why?
|
| Probability | 1 | 2010 | 167 | 0.080 |
Why?
|
| Sulfinpyrazone | 1 | 2009 | 2 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 136 | 0.080 |
Why?
|
| Probenecid | 1 | 2009 | 5 | 0.080 |
Why?
|
| Child | 3 | 2013 | 4189 | 0.080 |
Why?
|
| Diet | 1 | 2012 | 497 | 0.080 |
Why?
|
| Exercise | 1 | 2016 | 883 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 683 | 0.080 |
Why?
|
| Medical Order Entry Systems | 1 | 2008 | 42 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 2010 | 254 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 484 | 0.070 |
Why?
|
| Job Description | 1 | 2008 | 22 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 364 | 0.070 |
Why?
|
| New Hampshire | 1 | 2008 | 43 | 0.070 |
Why?
|
| Young Adult | 5 | 2016 | 4272 | 0.070 |
Why?
|
| Leukotriene Antagonists | 1 | 2007 | 8 | 0.070 |
Why?
|
| Motivation | 1 | 2010 | 274 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 180 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 453 | 0.070 |
Why?
|
| International Normalized Ratio | 3 | 2012 | 32 | 0.070 |
Why?
|
| Stroke | 2 | 2013 | 1127 | 0.070 |
Why?
|
| Data Collection | 1 | 2008 | 371 | 0.060 |
Why?
|
| Communication | 1 | 2011 | 546 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 94 | 0.060 |
Why?
|
| Disabled Persons | 1 | 2008 | 189 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 168 | 0.060 |
Why?
|
| Creatinine | 1 | 2006 | 128 | 0.060 |
Why?
|
| Physical Examination | 2 | 2016 | 104 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2005 | 56 | 0.060 |
Why?
|
| Adiponectin | 1 | 2024 | 34 | 0.060 |
Why?
|
| Arthritis | 1 | 2005 | 49 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 101 | 0.060 |
Why?
|
| Leptin | 1 | 2024 | 83 | 0.060 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.050 |
Why?
|
| Concept Formation | 1 | 2023 | 17 | 0.050 |
Why?
|
| Drug Monitoring | 3 | 2012 | 115 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 289 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 30 | 0.050 |
Why?
|
| Group Practice | 1 | 2003 | 12 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 130 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2003 | 52 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 142 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 140 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2003 | 147 | 0.050 |
Why?
|
| International Classification of Diseases | 2 | 2013 | 131 | 0.050 |
Why?
|
| Exercise Test | 1 | 2003 | 242 | 0.050 |
Why?
|
| Aspirin | 1 | 2003 | 167 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 163 | 0.050 |
Why?
|
| Internet | 1 | 2005 | 448 | 0.050 |
Why?
|
| Health Behavior | 1 | 2005 | 452 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2003 | 184 | 0.050 |
Why?
|
| Physician's Role | 1 | 2002 | 120 | 0.050 |
Why?
|
| Thalidomide | 1 | 2020 | 32 | 0.040 |
Why?
|
| Biomarkers | 2 | 2017 | 1307 | 0.040 |
Why?
|
| Febuxostat | 1 | 2020 | 2 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 13 | 0.040 |
Why?
|
| Echocardiography | 1 | 2003 | 457 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 27 | 0.040 |
Why?
|
| Biological Therapy | 1 | 2020 | 16 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 88 | 0.040 |
Why?
|
| Interdisciplinary Placement | 1 | 2018 | 1 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2013 | 1284 | 0.040 |
Why?
|
| Medical Records | 2 | 2012 | 133 | 0.040 |
Why?
|
| Infant | 2 | 2013 | 1492 | 0.040 |
Why?
|
| Patient Preference | 1 | 2018 | 78 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2017 | 48 | 0.030 |
Why?
|
| Computers | 1 | 2016 | 49 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2016 | 60 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 52 | 0.030 |
Why?
|
| Knee Injuries | 1 | 2016 | 47 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 210 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 171 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 58 | 0.030 |
Why?
|
| Health Facility Size | 1 | 2015 | 16 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 831 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 395 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 45 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 112 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 98 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2015 | 242 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 24 | 0.030 |
Why?
|
| New Zealand | 1 | 2013 | 37 | 0.030 |
Why?
|
| New England | 2 | 2004 | 267 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 71 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 79 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2013 | 44 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 64 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2012 | 52 | 0.030 |
Why?
|
| Urban Population | 1 | 2013 | 180 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 187 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 194 | 0.020 |
Why?
|
| Health Services Research | 1 | 2013 | 266 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 270 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 74 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 112 | 0.020 |
Why?
|
| Mortality | 1 | 2012 | 155 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 486 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 442 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 129 | 0.020 |
Why?
|
| Telephone | 1 | 2011 | 115 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 355 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1022 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 250 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1099 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1559 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 440 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2007 | 260 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 65 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 115 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2006 | 144 | 0.010 |
Why?
|
| Self Concept | 1 | 2005 | 105 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 35 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2004 | 88 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 101 | 0.010 |
Why?
|
| Patient Participation | 1 | 2005 | 216 | 0.010 |
Why?
|
| Medicare Part C | 1 | 2003 | 13 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 931 | 0.010 |
Why?
|
| Software | 1 | 2005 | 366 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 117 | 0.010 |
Why?
|